Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA, Trade Groups Team Up To Bolster Enforcement On Tainted Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA threatens to take "swift and strong" enforcement action without warning, including filing criminal charges, against manufacturers, suppliers and distributors of tainted supplements, according to a letter sent to industry Dec. 15.

You may also be interested in...



Weight Loss Products Provide Ample Targets In FDA War On Spiked Supplements

FDA finds four weight loss products that contain potentially dangerous undeclared ingredients, including DMAA and sibutramine. The agency also continues to warn about bee pollen with undeclared ingredients.

Weight Loss Products Provide Ample Targets In FDA War On Spiked Supplements

FDA finds four weight loss products that contain potentially dangerous undeclared ingredients, including DMAA and sibutramine. The agency also continues to warn about bee pollen with undeclared ingredients.

Industry Suggests Increase In Spiked Supplements Reflects FDA Investment In Testing, Targeted Selection

The number of products marketed as supplements and identified as tainted in 2013 grew 136% from 2011 – the year after FDA announced it would take “swift and strong” enforcement action. Trends in recalls and public notifications likely reflect FDA’s investment in testing products, a strategy in need of updating, supplement industry trade groups say.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel